biOasis Engages Kilmer Lucas for Cross-Border Investor Relations

RICHMOND, BRITISH COLUMBIA--(Marketwired - June 8, 2015) - BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF) (TSX VENTURE:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced today that it has retained Kilmer Lucas Inc. to provide it with Canadian and U.S. investor relations and strategic advisory services.

Kilmer Lucas combines a healthcare industry focus with a global reach. Working directly from its offices in Toronto, New York and San Francisco, and through a carefully assembled affiliate network that includes seasoned professionals based in Israel, Asia and Europe, Kilmer Lucas helps its clients to successfully navigate and penetrate the capital markets and media both at home and abroad. More information about the firm can be found at www.kilmerlucas.com.

"As biOasis continues to move aggressively forward into its commercialization phase, we are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader investor audience," said Rob Hutchison, biOasis' CEO.

Stephen Kilmer, President of Kilmer Lucas, commented, "We believe that a strong investment story is emerging at biOasis and we are excited that the company has chosen us to help tell it. Through the provision of a full range of investor relations and financial communications services, our primary goals will be to assist biOasis in achieving a fair and sustainable market valuation and to enhance the reputation that the company carries in the minds of investors, analysts and members of the media."

Under the terms of the agreement, BiOasis will pay Kilmer Lucas a monthly retainer fee of C$6,500 for its services. Should BiOasis uplist its common shares for trading to a national U.S. stock exchange while this agreement is in effect, the monthly retainer fee paid by it to Kilmer Lucas will automatically increase to US$7,500. The agreement, which commences immediately, has an initial term of 60 days. Following the end of the initial term, the agreement will renew automatically for 30-day periods unless terminated by either party.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada focused on overcoming the limitations of therapeutic drug delivery across the BBB. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"